Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rocco Liguori is active.

Publication


Featured researches published by Rocco Liguori.


Brain | 2014

Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy

Carla Giordano; Luisa Iommarini; Luca Giordano; Alessandra Maresca; Annalinda Pisano; Maria Lucia Valentino; Leonardo Caporali; Rocco Liguori; Stefania Deceglie; Marina Roberti; Francesca Fanelli; Flavio Fracasso; Fred N. Ross-Cisneros; Pio D’Adamo; Gavin Hudson; Angela Pyle; Patrick Yu-Wai-Man; Patrick F. Chinnery; Massimo Zeviani; Solange Rios Salomão; Adriana Berezovsky; Rubens Belfort; Dora Fix Ventura; Milton Rocha Moraes; Milton N. Moraes Filho; Piero Barboni; F. Sadun; Annamaria De Negri; Alfredo A. Sadun; Andrea Tancredi

The mechanisms of incomplete penetrance in Leber’s hereditary optic neuropathy are elusive. Giordano et al. show that mitochondrial DNA content and mitochondrial mass are both increased in tissues and cells from unaffected mutation carriers relative to affected relatives and control individuals. Upregulation of mitochondrial biogenesis may represent a therapeutic target.


Annals of Neurology | 2015

Syndromic parkinsonism and dementia associated with OPA1 missense mutations.

Valerio Carelli; Olimpia Musumeci; Leonardo Caporali; Claudia Zanna; Chiara La Morgia; Valentina Del Dotto; Anna Maria Porcelli; Michela Rugolo; Maria Lucia Valentino; Luisa Iommarini; Alessandra Maresca; Piero Barboni; Michele Carbonelli; Costantino Trombetta; Enza Maria Valente; Simone Patergnani; Carlotta Giorgi; Paolo Pinton; Giovanni Rizzo; Caterina Tonon; Raffaele Lodi; Patrizia Avoni; Rocco Liguori; Agostino Baruzzi; Antonio Toscano; Massimo Zeviani

Mounting evidence links neurodegenerative disorders such as Parkinson disease and Alzheimer disease with mitochondrial dysfunction, and recent emphasis has focused on mitochondrial dynamics and quality control. Mitochondrial dynamics and mtDNA maintenance is another link recently emerged, implicating mutations in the mitochondrial fusion genes OPA1 and MFN2 in the pathogenesis of multisystem syndromes characterized by neurodegeneration and accumulation of mtDNA multiple deletions in postmitotic tissues. Here, we report 2 Italian families affected by dominant chronic progressive external ophthalmoplegia (CPEO) complicated by parkinsonism and dementia.


Nature Genetics | 2015

Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder

Alexander J. Abrams; Robert B. Hufnagel; Adriana P. Rebelo; Claudia Zanna; Neville Patel; Michael Gonzalez; Ion J. Campeanu; Laurie B. Griffin; Saskia Groenewald; Alleene V. Strickland; Feifei Tao; Fiorella Speziani; Lisa Abreu; Rebecca Schüle; Leonardo Caporali; Chiara La Morgia; Alessandra Maresca; Rocco Liguori; Raffaele Lodi; Zubair M. Ahmed; Kristen L. Sund; Xinjian Wang; Laura A. Krueger; Yanyan Peng; Carlos E. Prada; Cynthia A. Prows; Elizabeth K. Schorry; Anthony Antonellis; Holly H. Zimmerman; Omar A. Abdul-Rahman

Dominant optic atrophy (DOA) and axonal peripheral neuropathy (Charcot-Marie-Tooth type 2, or CMT2) are hereditary neurodegenerative disorders most commonly caused by mutations in the canonical mitochondrial fusion genes OPA1 and MFN2, respectively. In yeast, homologs of OPA1 (Mgm1) and MFN2 (Fzo1) work in concert with Ugo1, for which no human equivalent has been identified thus far. By whole-exome sequencing of patients with optic atrophy and CMT2, we identified four families with recessive mutations in SLC25A46. We demonstrate that SLC25A46, like Ugo1, is a modified carrier protein that has been recruited to the outer mitochondrial membrane and interacts with the inner membrane remodeling protein mitofilin (Fcj1). Loss of function in cultured cells and in zebrafish unexpectedly leads to increased mitochondrial connectivity, while severely affecting the development and maintenance of neurons in the fish. The discovery of SLC25A46 strengthens the genetic overlap between optic atrophy and CMT2 while exemplifying a new class of modified solute transporters linked to mitochondrial dynamics.


Annals of Neurology | 2016

Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson disease

Vincenzo Donadio; Alex Incensi; Cristina Piccinini; Pietro Cortelli; Maria Pia Giannoccaro; Agostino Baruzzi; Rocco Liguori

To characterize the expression in skin nerves of native (n‐syn) and misfolded phosphorylated (p‐syn) α‐synucleins in pure autonomic failure (PAF) and idiopathic Parkinson disease (IPD). The specific aims were to (1) define the importance of n‐syn and p‐syn as disease biomarkers and (2) ascertain differences in abnormal synuclein skin nerve deposits.


Journal of Neuroimaging | 2014

Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in lewy body diseases: Complementary or alternative techniques?

Giorgio Treglia; Ernesto Cason; Pietro Cortelli; Anna Gabellini; Rocco Liguori; Antonio Bagnato; Alessandro Giordano; Giorgio Fagioli

To compare myocardial sympathetic imaging using 123I‐Metaiodobenzylguanidine (MIBG) scintigraphy and striatal dopaminergic imaging using 123I‐Ioflupane (FP‐CIT) single photon emission computed tomography (SPECT) in patients with suspected Lewy body diseases (LBD).


European Journal of Neurology | 2016

A multi-center, multinational age- and gender-adjusted normative dataset for immunofluorescent intraepidermal nerve fiber density at the distal leg

Vincenzo Provitera; Christopher H. Gibbons; Gwen Wendelschafer-Crabb; Vincenzo Donadio; D. F. Vitale; Annamaria Stancanelli; G. Caporaso; Rocco Liguori; Ningshan Wang; Lucio Santoro; William R. Kennedy; Maria Nolano

Quantification of intraepidermal nerve fibers (IENFs) in skin biopsies is now the tool of choice to diagnose small fiber neuropathies. An adequate normative dataset, necessary to assess normality cutoffs, is available for brightfield microscopy but not for immunofluorescence.


Journal of Neurology, Neurosurgery, and Psychiatry | 2015

LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population

Olimpia Musumeci; G. la Marca; Marco Spada; Stefania Mondello; Cesare Danesino; Giacomo P. Comi; Elena Pegoraro; Gabriele Antonini; Giovanni Marrosu; Rocco Liguori; Lucia Morandi; Maurizio Moggio; Roberto Massa; Sabrina Ravaglia; A di Muzio; Massimiliano Filosto; Paola Tonin; G. Di Iorio; Serenella Servidei; Gabriele Siciliano; C. Angelini; Tiziana Mongini; Antonio Toscano

Objective A multicentre observational study was aimed to assess the prevalence of late-onset Pompe disease (LOPD) in a large high-risk population, using the dried blood spot (DBS) as a main screening tool. Design/methods 17 Italian neuromuscular centres were involved in the late-onset Pompe early diagnosis (LOPED) study. Inclusion criteria were: (1) age ≥5u2005years, (2) persistent hyperCKaemia and (3) muscle weakness at upper and/or lower limbs (limb-girdle muscle weakness, LGMW). Acid α-glucosidase (GAA) activity was measured separately on DBS by fluorometric as well as tandem mass spectrometry methods. A DBS retest was performed in patients resulted positive at first assay. For the final diagnosis, GAA deficiency was confirmed by a biochemical assay in skeletal muscle, whereas genotype was assessed by GAA molecular analysis. Results In a 14-month period, we studied 1051 cases: 30 positive samples (2.9%) were detected by first DBS screening, whereas, after retesting, 21 samples were still positive. Biochemical and molecular genetic studies finally confirmed LOPD diagnosis in 17 cases (1.6%). The median time from the onset of symptoms/signs to diagnosis was 5u2005years. Among those patients, 35% showed presymptomatic hyperCKaemia and 59% showed hyperCKaemia+LGMW, whereas 6% manifested with LGMW. Conclusions LOPED study suggests that GAA activity should be accurately screened by DBS in all patients referring for isolated hyperCKaemia and/or LGMW. A timely diagnosis was performed in five patients with presymptomatic hyperCKaemia, but two had already manifested with relevant changes on muscle morphology and MRI. Consequently, enzyme replacement therapy was started in 14/17 patients, including the 2 patients still clinically presymptomatic but with a laboratory evidence of disease progression.


Movement Disorders | 2017

Neurophysiological correlates of abnormal somatosensory temporal discrimination in dystonia

Elena Antelmi; Roberto Erro; Lorenzo Rocchi; Rocco Liguori; Michele Tinazzi; Flavio Di Stasio; Alfredo Berardelli; John C. Rothwell; Kailash P. Bhatia

Somatosensory temporal discrimination threshold is often prolonged in patients with dystonia. Previous evidence suggested that this might be caused by impaired somatosensory processing in the time domain. Here, we tested if other markers of reduced inhibition in the somatosensory system might also contribute to abnormal somatosensory temporal discrimination in dystonia.


Brain | 2015

OPA1-related auditory neuropathy: site of lesion and outcome of cochlear implantation

Rosamaria Santarelli; Roberta Rossi; Pietro Scimemi; Elona Cama; Maria Lucia Valentino; Chiara La Morgia; Leonardo Caporali; Rocco Liguori; Vincenzo Magnavita; Anna Monteleone; Ariella Biscaro; Edoardo Arslan; Valerio Carelli

Santarelli et al. reveal that hearing impairments in patients carrying OPA1 missense mutations are the result of disordered synchrony in auditory nerve fibre activity owing to degeneration of terminal dendrites. Cochlear implantation improves speech perception and synchronous activation of auditory pathways in these patients by bypassing the lesion site.


Amyotrophic Lateral Sclerosis | 2014

Epidemiology of amyotrophic lateral sclerosis in Emilia Romagna Region (Italy): A population based study

Jessica Mandrioli; Sara Biguzzi; Carlo Guidi; Elisabetta Venturini; Elisabetta Sette; Emilio Terlizzi; Alessandro Ravasio; M. Casmiro; Fabrizio Salvi; Rocco Liguori; R. Rizzi; Vladimiro Pietrini; Elisabetta Chierici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Annamaria Borghi; Rita Rinaldi; Nicola Fini; Eleni Georgoulopoulou; Silvia de Pasqua; Marco Vinceti; Francesca Bonvicini; Salvatore Ferro; Roberto D’Alessandro

Abstract Our objective was to describe incidence and clinical features of ALS from a prospective population-based study in Emilia Romagna Region (ERR). From 2009 onwards, a prospective registry recorded all incident cases of ALS among residents in the ERR (population, 4.4 million inhabitants), involving 17 neurological departments. For each patient, detailed demographic and clinical information was collected by caring physicians. Results showed that from 1 January 2009 to 31 December 2011, 347 patients received a new diagnosis of ALS with a crude incidence rate of 2.63/100,000/year. There was micro-geographic heterogeneity throughout ERR, with higher incidence rates in the low density population (3.27/100,000) (p < 0.01). ALS patients have been more frequently employed in agriculture than the general ERR population (8.64% vs. 4.6%, p < 0.01). Clinical features were similar to those described in previous population based studies. In conclusion, we report incidence rates similar to those reported by European registries, reflecting good accuracy of our prospective study. We confirmed previous studies reporting higher incidence rates in rural areas and among agricultural workers. Although genetics has been gaining increasing importance in ALS aetiology, some epidemiological data are still unexplained. Identifying geographical areas or populations with high incidence rates can be a starting point for identifying environmental risk factors. Further studies having this specific aim can shed light on these topics.

Collaboration


Dive into the Rocco Liguori's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge